Published in Front Psychiatry on April 12, 2017
Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol (1973) 47.81
A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain (1988) 18.17
Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. J Neurosci Methods (1996) 6.41
Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J Pharmacol Exp Ther (1991) 2.96
U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist. J Pharmacol Exp Ther (1983) 2.65
Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol (1977) 2.61
In vitro models in the study of structure-activity relationships of narcotic analgesics. Annu Rev Pharmacol (1975) 2.47
Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol Pharmacol (1995) 2.34
Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc Natl Acad Sci U S A (2005) 2.29
A critique of fixed and progressive ratio schedules used to examine the neural substrates of drug reinforcement. Pharmacol Biochem Behav (1997) 2.28
The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br J Pharmacol (1977) 1.89
Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking. Proc Natl Acad Sci U S A (2009) 1.88
Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res Monogr (1998) 1.86
Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist. Eur J Pharmacol (2004) 1.66
Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1. J Pharmacol Exp Ther (1997) 1.59
Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse. J Pharmacol Exp Ther (1984) 1.45
Demonstration of tolerance to and physical dependence of N-allylnormorphine (nalorphine). J Pharmacol Exp Ther (1965) 1.45
Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor. J Pharmacol Exp Ther (1996) 1.39
Activity of the delta-opioid receptor is partially reduced, whereas activity of the kappa-receptor is maintained in mice lacking the mu-receptor. J Neurosci (1998) 1.35
Quantification of the analgesic activity of narcotic antagonists by a modified hot-plate procedure. J Pharmacol Exp Ther (1975) 1.32
A review of the properties of spiradoline: a potent and selective kappa-opioid receptor agonist. CNS Drug Rev (2003) 1.32
Nalbuphine. Drug Alcohol Depend (1985) 1.30
κ-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction. Trends Neurosci (2012) 1.29
Behavioral effects of a novel kappa opioid analgesic, U-50488, in rats and rhesus monkeys. Psychopharmacology (Berl) (1985) 1.26
The irreversible narcotic antagonistic and reversible agonistic properties of the fumaramate methyl ester derivative of naltrexone. Eur J Pharmacol (1981) 1.16
Prediction of abuse liability of drugs using IV self-administration by rats. Psychopharmacology (Berl) (1984) 1.15
Activity of opioid ligands in cells expressing cloned mu opioid receptors. BMC Pharmacol (2003) 1.11
Determination of receptors that mediate opiate side effects in the mouse. Br J Pharmacol (1983) 1.06
Quantitative studies of the antagonism of morphine by nalorphine and naloxone. J Pharmacol Exp Ther (1969) 1.04
Opioid efficacy in a C6 glioma cell line stably expressing the human kappa opioid receptor. J Pharmacol Exp Ther (1999) 1.04
The kappa opioid receptor antagonist JDTic attenuates alcohol seeking and withdrawal anxiety. Addict Biol (2012) 1.03
Bremazocine: a kappa-opioid agonist with potent analgesic and other pharmacologic properties. CNS Drug Rev (2005) 1.00
Evaluation in nonhuman primates: evaluation of the physical dependence capacities of oripavine-thebaine partial agonists in patas monkeys. Adv Biochem Psychopharmacol (1973) 0.96
Blockade of morphine reward through the activation of kappa-opioid receptors in mice. Neuropharmacology (1993) 0.95
Dopamine-dependent behavioural stimulation by non-peptide delta opioids BW373U86 and SNC 80: 2. Place-preference and brain microdialysis studies in rats. Behav Pharmacol (1998) 0.94
Delta opioid receptors in brain function and diseases. Pharmacol Ther (2013) 0.91
Tramadol acts as a weak reinforcer in the rat self-administration model, consistent with its low abuse liability in humans. Pharmacol Biochem Behav (2010) 0.89
Effects of levorphanol and several kappa-selective opioids on respiration and behavior in rhesus monkeys. J Pharmacol Exp Ther (1988) 0.87
Pharmacological profiles of opioid ligands at kappa opioid receptors. BMC Pharmacol (2006) 0.87
Dependence studies on new compounds in the rhesus monkey, rat and mouse (1989). NIDA Res Monogr (1989) 0.86
The clinical usefulness of agonist-antagonist analgesics in acute pain. Drug Alcohol Depend (1987) 0.85
Reversal by beta-funaltrexamine of the antinociceptive effect of opioid agonists in the rat. Br J Pharmacol (1986) 0.84
Mu antagonist and kappa agonist properties of beta-funaltrexamine (beta-FNA) in vivo: long-lasting spinal analgesia in mice. J Pharmacol Exp Ther (1990) 0.84
Nalfurafine hydrochloride to treat pruritus: a review. Clin Cosmet Investig Dermatol (2015) 0.83
Effect of the highly selective and nonpeptide delta opioid receptor agonist TAN-67 on the morphine-induced place preference in mice. J Pharmacol Exp Ther (1996) 0.83
AT-1001: a high-affinity α3β4 nAChR ligand with novel nicotine-suppressive pharmacology. Br J Pharmacol (2015) 0.83
Lack of dependence and rewarding effects of deltorphin II in mu-opioid receptor-deficient mice. Eur J Neurosci (2001) 0.81
A key role for the N/OFQ-NOP receptor system in modulating nicotine taking in a model of nicotine and alcohol co-administration. Sci Rep (2016) 0.79
The antinociceptive properties of reboxetine in acute pain. Eur Neuropsychopharmacol (2009) 0.78
Butorphanol agonist effects and acute physical dependence in opioid abusers: comparison with morphine. Drug Alcohol Depend (1998) 0.78
Butorphanol. Drug Alcohol Depend (1985) 0.78
Comparative rewarding properties of morphine and butorphanol. Brain Res Bull (1995) 0.77
Analgesics 4. Studies on the effects of the introduction of methyl at C-17 of N-cyclopropylmethyl-normorphine: synthesis, receptor binding, in vivo activity, conformation energies. NIDA Res Monogr (1987) 0.76
Pharmacological characteristics of agonist-antagonist analgesics. Drug Alcohol Depend (1987) 0.76
N-substituent modulation of opiate agonist/antagonist activity in resolved 3-methyl-3-(m-hydroxyphenyl)piperidines. J Med Chem (1986) 0.76
1989 Annual Report, evaluation of new compounds for opioid activity. NIDA Res Monogr (1989) 0.76
Rodent motor and neuropsychological behaviour measured in home cages using the integrated modular platform SmartCage™. Clin Exp Pharmacol Physiol (2012) 0.93
Pharmacological stress is required for the anti-alcohol effect of the α3β4* nAChR partial agonist AT-1001. Neuropharmacology (2015) 0.90
AT-1001: a high-affinity α3β4 nAChR ligand with novel nicotine-suppressive pharmacology. Br J Pharmacol (2015) 0.83
Selective κ receptor partial agonist HS666 produces potent antinociception without inducing aversion after i.c.v. administration in mice. Br J Pharmacol (2017) 0.76